FDA OKs oral semaglutide pill
The FDA approved oral semaglutide as the first GLP‑1 pill for chronic weight management following positive phase III data, including cardiometabolic improvements in trial results. Investors reacted by re‑weighing market positions in the obesity‑drug race, with commentary noting Eli Lilly’s competitive momentum relative to Novo Nordisk. ( )
Weight-loss drugs that mimic a gut hormone started as shots. On December 22, 2025, the Food and Drug Administration approved Novo Nordisk’s once-daily Wegovy pill, the first oral glucagon-like peptide-1 drug for chronic weight management in the United States. (prnewswire.com) The pill is approved for adults with obesity, or adults who are overweight and have at least one weight-related condition, alongside diet and physical activity. The Food and Drug Administration label also says it can reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. (accessdata.fda.gov) In the phase 3b OASIS 4 trial, adults taking oral semaglutide 25 milligrams once a day lost an average of 13.6% of body weight at 64 weeks, versus 2.2% with placebo. The trial included 307 adults with obesity or overweight and at least one coexisting condition, but not diabetes. (nejm.org) A separate East Asian trial of oral semaglutide 50 milligrams ran 68 weeks and reported a 13.1 percentage-point advantage over placebo, along with improvements in cardiometabolic risk factors. Those measures include blood sugar, blood pressure, and blood fats linked to heart disease. (jamanetwork.com) The approval moved obesity treatment further from injections toward pills. Novo Nordisk launched the product in the United States in early January 2026, giving it the first oral entry in a market that had been dominated by weekly shots such as Wegovy injection and Zepbound. (ajmc.com, fda.gov) That head start did not last long. On April 1, 2026, the Food and Drug Administration approved Eli Lilly’s oral obesity drug orforglipron, sold as Foundayo, making it the second pill in the category and setting up a direct commercial fight with Novo Nordisk. (reuters.com, statnews.com) Investors have been weighing that rivalry for months. CNBC reported on February 4, 2026, that Lilly had taken a clear edge in market share in obesity and diabetes drugs, helped by stronger injections and an earlier direct-to-consumer push. (cnbc.com) Novo Nordisk has tried to answer with comparative data. In an April 2, 2026, company release, it said an indirect comparison found Wegovy pill produced greater weight loss and lower odds of stopping treatment from side effects than orforglipron, but the analysis was not a head-to-head trial. (novonordisk-us.com) The pill still carries the class’s familiar limits. The prescribing information includes a boxed warning about thyroid C-cell tumors seen in rodents, and it says the drug should not be used with other semaglutide-containing products or other glucagon-like peptide-1 receptor agonists. (accessdata.fda.gov) The opening move in obesity care was weekly injections. By April 2026, the contest had shifted to who can make a daily pill easier to get, easier to stay on, and easier to pay for. (bloomberg.com, cnbc.com)
